Maryam Nourizadeh, Mahsa Fattahi,
Volume 14, Issue 4 (Volume 14, No 4 2024)
Abstract
Methotrexate (MTX) is a freely available medication. However, regardless of extensive off-label consumption, FDA labeling does not include accepted for the consumption of MTX for many inflammatory skin diseases in pediatrics, containing morphea, psoriasis, atopic dermatitis, and alopecia areata. Lacking published healing recommendations makes the clinicians unsure about prescribing MTX in an off-label manner especially in children. Present study, was conducted to review the use of MTX to heal pediatric inflammatory skin disorders.
The evidence and consent based advices will assistance safe and successful use of MTX for the underserved population of pediatrics who may benefit from this valuable, time-honored medication.
